In vitro and In vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 Against Multiple Myeloma Cells

類似資料

• Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells
  著者:: Tian, Ze, 等
  出版事項: (2012)
• Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
  著者:: Hideshima, Teru, 等
  出版事項: (2005)
• Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies
  著者:: Lee, Edmund C., 等
  出版事項: (2011)
• A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
  著者:: Chauhan, Dharminder, 等
  出版事項: (2010)
• Preclinical Evaluation of a Novel SIRT1 Modulator SRT1720 in Multiple Myeloma Cells
  著者:: Chauhan, Dharminder, 等
  出版事項: (2011)